Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560589 | 1.00 | BCL3 (0.63) | BCL3ALDH1A1GAAKMT2ADRD4 | |
| SCHEMBL30560605 | 0.91 | BCL3 (0.62) | BCL3ALDH1A1GAAKMT2ADRD4 | |
| SCHEMBL17554158 | 0.91 | BCL3 (0.62) | BCL3ALDH1A1GAAKMT2ADRD4 | |
| SCHEMBL17554066 | 0.91 | BCL3 (0.78) | BCL3ALDH1A1GAAKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL17554124 | 0.90 | BCL3 (0.76) | BCL3ALDH1A1GAAKMT2ALMNA | |
| SCHEMBL17554093 | 0.90 | BCL3 (0.60) | BCL3ALDH1A1GAAKMT2AHTT | |
| SCHEMBL19348436 | 0.88 | BCL3 (0.80) | BCL3ALDH1A1GAAKMT2AHTT | |
| SCHEMBL30560485 | 0.88 | BCL3 (0.80) | BCL3ALDH1A1GAAKMT2AHTT | |
| SCHEMBL17554055 | 0.87 | BCL3 (0.73) | BCL3ALDH1A1GAAKMT2ALMNA | |
| Malonic Acid SCHEMBL17554116 | 0.87 | BCL3 (0.73) | BCL3ALDH1A1GAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| EP-3174602-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016728-A2 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | BCL3 1/4885ALDH1A1 2635/4885GAA 4322/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | BCL3 1/4885ALDH1A1 2830/4885GAA 4220/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | BCL3 1/4885ALDH1A1 2830/4885GAA 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.